Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ĭɳ¶«¾Å¼ÛHPVÒßÃçÔÚ»ª»ñÅúÄÐÐÔ˳Ӧ֤ | 1·ÖÖÓÒ©ÎÅËÙÀÀ

2025-04-14
|
»á¼ûÁ¿£º

0415.jpgÒ½ÏßÒ©ÎÅ

1. 4ÔÂ14ÈÕ£¬£¬£¬£¬£¬£¬Ä¬É³¶«Ðû²¼£¬£¬£¬£¬£¬£¬¼Ñ´ïÐÞ?9[¾Å¼ÛÈËÈéÍ·Áö²¡¶¾ÒßÃ磨Äð¾Æ½Íĸ£©]¶àÏîÐÂ˳Ӧ֤ÒÑ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖµÄÉÏÊÐÅú×¼£¬£¬£¬£¬£¬£¬ÊÊÓÃÓÚ16~26ËêÄÐÐÔ½ÓÖÖ¡£¡£¡£¡£¡£

2. 4ÔÂ13Èյ磬£¬£¬£¬£¬£¬ºãÈðҽҩͨ¸æ£¬£¬£¬£¬£¬£¬¹«Ë¾×¢ÉäÓÃHRS-9190¡¢SHR-3792×¢ÉäÒº»ñÅúÁÙ´²¡£¡£¡£¡£¡£×¢ÉäÓÃHRS-9190ΪÊõÖÐÓÃÒ©µÄ1ÀàÐÂÒ©£¬£¬£¬£¬£¬£¬ÓÃÓÚÈ«ÉíÂé×íÓÕµ¼ÆÚÆø¹Ü²å¹Ü¼°Î¬³ÖÊõÖйÇ÷À¼¡ËÉи £»£»£»SHR-3792×¢ÉäÒºÊǹ«Ë¾×ÔÖ÷Ñз¢µÄÁ¢ÒìÐÍ¿¹Ö×ÁöºòѡҩÎï¡£¡£¡£¡£¡£

3. 4ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬»ªÈó²©ÑÅÉúÎïÖÆÒ©¼¯ÍŹɷÝÓÐÏÞ¹«Ë¾Ðû²¼ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄƤÏÂ×¢ÉäÈËÃâÒßÇòÂѰס¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·(֪ͨÊé±àºÅ£º2025LP01029)£¬£¬£¬£¬£¬£¬Åú׼ƤÏÂ×¢ÉäÈËÃâÒßÇòÂѰ׿ªÕ¹Ô­·¢ÐÔÃâÒßÇòÂѰ×ȱ·¦Ö¢£¬£¬£¬£¬£¬£¬ÈçXÁªËøµÍÃâÒßÇòÂѰ×Ѫ֢£¬£¬£¬£¬£¬£¬³£¼û±äÒìÐÔÃâÒßȱÏݲ¡£¬£¬£¬£¬£¬£¬ÃâÒßÇòÂѰ×GÑÇÐÍȱÏݲ¡µÈÁÙ´²ÊÔÑé¡£¡£¡£¡£¡£

4. ¿ËÈÕ£¬£¬£¬£¬£¬£¬Î人È˸£Àû¿µÒ©ÒµÓÐÏÞ¹«Ë¾ÑÎËá°¢±È¶à¶ûƬ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©Åú׼ǩ·¢µÄ¡¶Ò©Æ·×¢²áÖ¤Êé¡·£¬£¬£¬£¬£¬£¬¸ÃÆ·ÖÖÆ¾Ö¤»¯Ñ§Ò©Æ·3Àà»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬ÊÓͬͨ¹ýÒ»ÖÂÐÔÆÀ¼Û£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆÓÉA¡¢BÐÍÁ÷¸Ð²¡¶¾ÒýÆðµÄÉϺôÎüµÀѬȾ¡£¡£¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. 4ÔÂ14ÈÕ£¬£¬£¬£¬£¬£¬ÂõÍþÉúÎ688062.SH£©ÓëÉîÊÆ¿Æ¼¼ÅäºÏÐû¹«¸æ¿¢Õ½ÂÔÏàÖú¡£¡£¡£¡£¡£Ë«·½½«³ä·ÖÑéÕ¹¸÷×ÔÔÚÉúÎïÒ©Ñз¢ºÍÈ˹¤ÖÇÄÜ£¨AI£©´óÄ£×ÓÁìÓòµÄÓÅÊÆ£¬£¬£¬£¬£¬£¬ÅäºÏ´òÔìÉúÎïÒ©Ñз¢´óÄ£×ÓÆ½Ì¨£¬£¬£¬£¬£¬£¬¹²ÖþÁ¢ÒìÒ©Ñз¢Ð·¶Ê½¡£¡£¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 4ÔÂ9ÈÕ£¬£¬£¬£¬£¬£¬NatureÔÓÖ¾µÄÒ»Ïî×îÐÂÑо¿Í¨¹ý¶Ô½ü200Íò¸öÌ壨48.9Íò²¡Àý£¬£¬£¬£¬£¬£¬147.2Íò±ÈÕÕ£©¿ªÕ¹È«»ùÒò×鹨ÁªÆÊÎö£¨GWAS£©£¬£¬£¬£¬£¬£¬·¢Ã÷ÁË962¸ö×ÔÁ¦ÒÅ´«¹ØÁªÐźţ¨ÆäÖÐ513¸öΪз¢Ã÷£©£¬£¬£¬£¬£¬£¬²¢Á¬Ïµµ¥Ï¸°û¶à×éѧ¡¢¹¦Ð§ÑéÖ¤¼°ÁÙ´²Êý¾ÝÆÊÎö£¬£¬£¬£¬£¬£¬Õ¹ÏÖÁ˹ÇÊàŦÑ×ÒÅ´«»úÖÆµÄÒªº¦Í¨Â·ÓëDZÔÚÒ©Îï°Ðµã¡£¡£¡£¡£¡£

[1]Hatzikotoulas, K., Southam, L., Stefansdottir, L. et al. Translational genomics of osteoarthritis in 1,962,069 individuals. Nature (2025). https://doi.org/10.1038/s41586-025-08771-z

Ïà¹ØÐÂÎÅ
ÖÆÒ©¾ÞÍ·½ü5ÄêÐÂҩЧ¹û±ÈÆ´£ºÄ¬É³¶«µÇ¶¥
2017-05-10
Ò»ÄêÄÚÐÂÒ©»ñÅúÉÏÊеÄÊýĿͨ³£±»ÊÓΪҩÆóÉú²úÁ¦µÄÇçÓê±í£¬£¬£¬£¬£¬£¬EP Vantage¿ËÈÕ¶Ô½ü5Ä꽫ÐÂÒ©ÍÆÏòÊг¡µÄÖ÷Òª¹«Ë¾¾ÙÐÐÁËÊáÀí£¬£¬£¬£¬£¬£¬²¢ÆÊÎöÁËÄÇЩЧ¹ûì³È»µÄ¹«Ë¾¡£¡£¡£¡£¡£
ASCO2016£ºÄ¬É³¶«PD-1ÃâÒßÁÆ·¨Keytruda¶àÖÖ×éºÏ¼Æ»®ÖÎÁÆÍíÆÚÐþÉ«ËØÁöÌåÏÖÆð¾¢Êý¾Ý
2016-06-06
¹úÖÆÒ©¾ÞͷĬɳ¶«£¨Merck & Co£©¿ËÈÕÔÚ2016ÄêµÚ52½ìÃÀ¹úÁÙ´²Ö×Áöѧ»á£¨ASCO£©Äê»áÉÏÐû²¼ÁËPD-1ÃâÒßÁÆ·¨Keytruda£¨pembrolizumab£©ÁªºÏÆäËûÖÎÁƼƻ®£¨°üÀ¨°©Ö¢ÒßÃçT-vec¡¢dabrafenib+trametinib¡¢µÍ¼ÁÁ¿ipilimumab£©ÖÎÁÆÍíÆÚÐþÉ«ËØÁöµÄ3¸öÑо¿µÄÊý¾Ý¡£¡£¡£¡£¡£
Ĭɳ¶«6ÒÚ¼ÓÂëÖ×ÁöÃâÒßÁÆ·¨
2015-08-19
¿ËÈÕ£¬£¬£¬£¬£¬£¬Ä¬É³¶«ÓëÒÔÉ«ÁÐÉúÎï¿Æ¼¼cCAMBiotherapeutics¹«Ë¾¸æ¿¢Ò»Ïî¼ÛÖµ6.05ÒÚÃÀÔªµÄÏàÖúЭÒ飬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚÅäºÏÑз¢ÐÂÒ»´úÖ×ÁöÖÎÁÆÒ©Îï¡£¡£¡£¡£¡£Æ¾Ö¤Ð­ÒéÄÚÈÝ£¬£¬£¬£¬£¬£¬Ä¬É³¶«½«ÒÔ9500ÍòÃÀ½ðµÄÏÖ½ð×÷ΪԤ¸¶¿î»»È¡cCAMµÄËùÓÐÒÑ¿¯Ðйɷݡ£¡£¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿